Advances in drug eluting stents – focus on the Endeavor^® zotarolimus stent

Review

(4253) Views  (1232) Full article downloads

Authors: Jonathan Bridges, Donald Cutlip

Published Date December 2008 Volume 2009:2 Pages 1 - 8

DOI: http://dx.doi.org/10.2147/MDER.S3071

Jonathan Bridges, Donald Cutlip

Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

Abstract: Coronary artery disease remains one of the leading causes of death in the United States. Over the last 30 years, the development of coronary artery angioplasty and stenting has drastically reduced mortality during acute coronary syndromes while also reducing symptoms of chronic coronary artery disease. Unfortunately, the placement of stents in a coronary artery can be complicated by in-stent thrombosis or restenosis. In 2003–2004, a new generation of stents was introduced to the market with the goal of reducing the rate of restenosis. These stents, called drug eluting stents (DES), are coated with a pharmacological agent designed to reduce the neointimal hyperplasia associated with restenosis. Within a year, approximately 80% of all percutaneous coronary interventions performed within the US involved placement of a DES. In 2006, a controversy arose about the possibility of a statistically significant increased risk of acute stent thrombosis associated with DES especially when used for an “off label” indication. This risk was attributed to delayed endothelization. This controversy has led to a reduction in the use of DES along with longer use of dual platelet inhibition with aspirin and clopidogrel. Recently Medtronic introduced a new DES to the market called the Endeavor^® stent – a zotarolimus eluting stent.

Keywords: Endeavor^® stent, zotarolimus stent, drug eluting stent

Readers of this article also read: